News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Phosphagenics Limited Initiates Anti-Cancer Compound Animal Trials
January 24, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne's Phosphagenics (ASX:POH, AIM:PSG) will commence animal studies later this month on its patented anti-cancer compound. More...
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Australia
MORE ON THIS TOPIC
Neurodegenerative disease
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears
May 1, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks
April 30, 2026
·
5 min read
·
Gabrielle Masson
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
April 30, 2026
·
2 min read
·
Heather McKenzie
Alzheimer’s disease
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
April 30, 2026
·
2 min read
·
Tristan Manalac
